PubRank

PD-1 Inhibitors Consolidation in Extensive-stage Small Cell Lung Cancer (PICARES)

Clinical Trial ID NCT03971214

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT03971214

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Global cancer statistics, 2012. CA Cancer J Clin 2015 53.52
2 The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012 24.94
3 PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008 19.24
4 Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012 13.12
5 Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med 2015 12.54
6 Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 2002 12.39
7 Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 2015 8.64
8 Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006 7.87
9 Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet 2014 6.64
10 Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999 5.84
11 Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 2009 4.58
12 Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst 2013 3.07
13 Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest 2014 3.06
14 Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 2002 2.89
15 Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 2009 2.73
16 Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys 2013 2.28
17 Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen. Cancer Immunol Res 2014 2.00
18 Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol 2015 1.74
19 Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4-CD8-) thymocytes. Int Immunol 1996 1.68
20 Maximizing tumor immunity with fractionated radiation. Int J Radiat Oncol Biol Phys 2011 1.60
21 Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. Cancer Res 2012 1.59
22 Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol 2016 1.55
23 Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy. Ann Oncol 2015 1.54
24 Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res 2014 1.52
25 Effect of host immune capability on radiocurability and subsequent transplantability of a murine fibrosarcoma. J Natl Cancer Inst 1979 1.48
26 Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol 2012 1.43
27 Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol 2017 1.41
28 Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer. J Clin Oncol 2009 1.30
29 Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America. Cancer 2002 1.25
30 The confluence of stereotactic ablative radiotherapy and tumor immunology. Clin Dev Immunol 2011 1.05
31 Radiotherapy for extensive stage small-cell lung cancer - Authors' reply. Lancet 2015 0.85
32 Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med 2017 0.75
33 Cancer incidence and mortality in China in 2013: an analysis based on urbanization level. Chin J Cancer Res 2017 0.75
Next 100